Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
538 Leser
Artikel bewerten:
(2)

Tracelink, Inc.: TraceLink's 2023 Success: Expanded Digitalization Capabilities and Growing Adoption of New Supply Chain Solutions

BOSTON, Feb. 5, 2024 /PRNewswire/ -- TraceLink, the world's largest digital network platform for healthcare and life sciences, expanded its digitalization capabilities in 2023, leading to an annual increase of more than 300 new customers. Utilizing the industry's largest integrated digital network of over 290,000 entities, TraceLink is working to revolutionize the way businesses orchestrate the digital journeys of products, processes, and partners that span the end-to-end supply chain, resulting in the following 2023 achievements:


Customer Growth: Surpassing 1,600 total customers, an increase of 23%, a testament to the market's confidence in TraceLink's unique supply chain digitalization model. These 1,600+ customers' supply chain activities operate in over 100 countries globally.

Solution Adoption: 50+ new clients in 2023 selected TraceLink's cutting-edge solutions in orchestration intelligence, partner orchestration, and process orchestration, demonstrating broad industry demand for end-to-end supply chain digitalization capabilities.

Successful Implementations: 510 customer implementation projects were deployed on the TraceLink network in 2023, demonstrating the effectiveness of TraceLink's unique Integrate-Once partner integration and solution delivery model.

"Our team's relentless focus on customer enablement and success, and our ability to meet rapidly changing supply chain demands through our proven network integration capabilities, have been key drivers of our growth this year. Eclipsing more than 1,600 total customers in 2023 is a clear indication that our vision and maturing set of product, partner, and process orchestration capabilities is resonating with the market," said Shabbir Dahod, President & CEO, TraceLink.

The growth was fueled by the introduction of a range of new solutions aimed at tackling the industry's most intricate multienterprise challenges:

  • Product Availability Intelligence (PAI): Designed to enhance product availability and minimize shortages by leveraging advanced analytics and real-time data to predict them 90 days in advance.
  • Multienterprise Information Network Tower (MINT): Enabling 100% partner integration, at an affordable cost, to provide a comprehensive view across the supply chain, facilitating better decision-making through increased visibility and collaboration.
  • Supply Chain Work Management for Compliance Exceptions (SCWM): Facilitating the management and resolution of compliance exceptions efficiently, ensuring regulatory adherence while maintaining supply chain integrity.
  • Compliance Solutions for Emerging Markets: Supporting regulatory requirements in Kazakhstan, Kyrgyzstan, and other emerging markets, aiding businesses in navigating complex compliance landscapes.
  • Expanded DSCSA Capabilities: Streamlining compliance with the Drug Supply Chain Security Act (DSCSA), improving traceability and security in pharmaceutical supply chains while providing operational efficiency.

These new offerings underscore TraceLink's unwavering commitment to solving the most pressing challenges of supply chain orchestration. TraceLink's efforts in digitalizing the supply chain continue to set the industry standard, demonstrating how strategic innovation can lead to tangible improvements in efficiency, compliance, and collaboration across the global healthcare and life sciences sector.

For more information, please visit www.tracelink.com.

About TraceLink Inc.:
TraceLink Inc. is the leading digital network platform company, enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of pharmaceuticals, ensuring that every patient gets the medicines they need when needed, safely and securely. For more information, visit www.tracelink.com.

Contact:
Erica Burns
edurham@tracelink.com

Logo - https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tracelinks-2023-success-expanded-digitalization-capabilities-and-growing-adoption-of-new-supply-chain-solutions-302053726.html

© 2024 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.